Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Accelerate to discover
Related topics
Aug 17, 2023
Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...
Optimizing Gene Expression with Bioluminescence & the piggyBac System
Aug 15, 2023
Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...
High-plex immunofluorescence imaging and traditional histology of the same tissue section
Aug 7, 2023
RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...
Drive key insights and discoveries with NEW Live Cell Analysis applications for eSight system
Aug 2, 2023
eSight is now powerful like never before. Learn more about new dedicated application modules for live-cell analysis: 3D...
Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis
Jul 14, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...
MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood
Jul 12, 2023
MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...
43 markers, ONE tube : Impress yourself with Cytek Aurora Spectral Cytometer
Jul 11, 2023
Using Cytek full spectrum flow cytometry, scientists at Hamad Medical Corporation, developed a 43 color panel to...
InAlyzer - The technology chosen by NASA
Jul 10, 2023
MEDIKORS's InAlyzer was finally selected as the equipment to be used for NASA's space environment biological research
Nov 23, 2017
Nonalcoholic fatty liver disease (NAFLD) directly affects 10–30% of the human population and is characterized by pathological alterations ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and irreversible cirrhosis. NAFLD is considered a hepatic component of metabolic syndromes and is thus strongly associated with metabolic diseases such as obesity, insulin resistance, hypertension, and dyslipidemia. The prevalence of NAFLD is strongly associated with obesity and the metabolic complications of over-nutrition, which usually accompany visceral obesity. Visceral obesity is particularly associated with NAFLD. The amount of visceral fat is directly linked to the severity of liver inflammation and fibrosis in NAFLD. Human and animal studies indicate that NAFLD is strongly associated with VAT inflammation and elevated circulating inflammatory factors such as inflammatory adipokines and lipids. It is reasonable that targeting visceral adipose tissue (VAT) can contribute to the treatment and prevention of NAFLD. Accordingly, we thought it plausible that the anti-angiogenic-induced VAT loss may attenuate NAFLD during obesity.
Visualization of real-time visceral adipose tissue vasculature was performed using an FCFM imaging system (Cellvizio, Mauna Kea Technologies) with excitation and emission wavelengths of 488 and 520 nm, respectively.
Get more info
Brand profile
Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
More info at:
www.cellviziolab.com/